A method called "in vivo CAR-T (in vivo CAR-T·intra-body CAR-T)" that directly alters immune cells within the body with a single injection is recently changing the landscape of the cancer treatment ...

Within this global landscape, the EXO 001 targeted exosome platform--developed jointly by CMUH and Ever Supreme Bio Technology--stands out for its use of high-biocompatibility, naturally derived ...

The deal gets Lilly access to Orna’s in vivo CAR T technology. The biotech’s lead asset, which has yet to start clinical ...

CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to isolate and ...

Worth up to $2.4 billion, the acquisition is also the latest in a series of buyouts involving startups with technologies that modify immune cells inside the body.

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular therapy in multiple myeloma by reducing manufacturing, treatment delays, and ...

This webinar will highlight how circular RNA overcomes key challenges in in vivo CAR-T therapy, with case examples from YXgene’s circRNA platform. In vivo CAR-T therapy is emerging as a transformative ...

LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like cancer, there’s a lot of pressure to optimize these therapies. This is ...

Eli Lilly has signed its second pipeline-building deal in two days, reaching an agreement to buy in vivo CAR-T developer Orna ...

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

So normally the way we give CAR-T is that we take out the T-cells from patients, then we engineer them to attack them myeloma, and then we give them back to them. But that takes time because ...